tbuckley/cabot-search huggingface dataset:
Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B
Authors: Chia‐Ming Chu, Yun‐Fan Liaw
Journal: Hepatology (2018)

Potential conflict of interest: Nothing to report. To the Editor: The large cohort study of Fung et al.(1) in Hepatology described 18‐year outcomes of chronic hepatitis B virus (HBV) infection after hepatitis B e antigen (HBeAg) seroconversion (ESC) and constructed scores predicting hepatocellular carcinoma (HCC) and hepatitis B surface antigen seroclearance. Although the number of patients and the duration of follow‐up are impressive, several points require clarification or further discussion. First, given that the durability of spontaneous and antiviral‐therapy–related ESC is different,(2) it seems not appropriate to lump 219 patients who had received antiviral therapy and the 504 untreated patients together as a cohort. The patients on antiviral therapy should be excluded or compared with the untreated patients with ESC. Second, the predictors identified in the study have long been well known, as reviewed in a 2009 article.(3) Furthermore, genotype C infection is dominant over genotype B in Hong Kong patients, but its role was not addressed in this Hong Kong study, although it was found to be a significant factor for delayed ESC and subsequent HBeAg‐negative hepatitis, cirrhosis, and HCC. Third, the investigators seem not to be aware that significant correlation of age at ESC and risk of cirrhosis with a hazard ratio of 3.4 per 10‐year increase of age (P = 0.006) was recognized in 2004.(4) Also not cited in this study are earlier and subsequent studies that have further shown that ESC age over 40 is associated with significantly higher risk for subsequent HBV reactivation, cirrhosis, and HCC,(3) possibly because prolonged immune clearance phase with active viral replication and necroinflammation in delayed seroconverters may have led to higher fibrosis stage, even cirrhosis preceding time of ESC. Fourth, cirrhosis is the most important factor for HCC. However, this study did not address the important questions, including the number of patients, timing, and predictors of cirrhosis development, at all. Moreover, the REVEAL‐HBV (Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer‐Hepatitis B Virus) study has shown that HBV‐DNA levels, genotype C HBV infection, basal core promoter mutation, and male sex are not risk factors for HCC after the onset of liver cirrhosis. The predictors for HCC in patients with cirrhosis might be different from the predictors for cirrhosis/HCC in patients without cirrhosis. It is highly suggested that patients with cirrhosis at the time of ESC should be excluded from the analysis of factors predictive for cirrhosis and HCC after ESC.
Biallelic Expression of Mucin-1 in Autosomal Dominant Tubulointerstitial Kidney Disease: Implications for Nongenetic Disease Recognition
Authors: Karl X. Knaup, Thomas Hackenbeck, Bernt Popp, Johanna Stoeckert, Andrea Wenzel, Maike Büttner-Herold, Frederick Pfister, Markus Schueler, Didem Seven, Annette M. May, Jan Halbritter, Hermann-Josef Gröne, André Reis, Bodo B. Beck, Kerstin Amann, Arif B. Ekici, Michael S. Wiesener
Journal: Journal of the American Society of Nephrology (2018)

Background Providing the correct diagnosis for patients with tubulointerstitial kidney disease and secondary degenerative disorders, such as hypertension, remains a challenge. The autosomal dominant tubulointerstitial kidney disease (ADTKD) subtype caused by MUC1 mutations (ADTKD- MUC1 ) is particularly difficult to diagnose, because the mutational hotspot is a complex repeat domain, inaccessible with routine sequencing techniques. Here, we further evaluated SNaPshot minisequencing as a technique for diagnosing ADTKD- MUC1 and assessed immunodetection of the disease-associated mucin 1 frameshift protein (MUC1-fs) as a nongenetic technique. Methods We re-evaluated detection of MUC1 mutations by targeted repeat enrichment and SNaPshot minisequencing by haplotype reconstruction via microsatellite analysis in three independent ADTKD- MUC1 families. Additionally, we generated rabbit polyclonal antibodies against MUC1-fs and evaluated immunodetection of wild-type and mutated allele products in human kidney biopsy specimens. Results The detection of MUC1 mutations by SNaPshot minisequencing was robust. Immunostaining with our MUC1-fs antibodies and an MUC1 antibody showed that both proteins are readily detectable in human ADTKD- MUC1 kidneys, with mucin 1 localized to the apical membrane and MUC1-fs abundantly distributed throughout the cytoplasm. Notably, immunohistochemical analysis of MUC1-fs expression in clinical kidney samples facilitated reliable prediction of the disease status of individual patients. Conclusions Diagnosing ADTKD- MUC1 by molecular genetics is possible, but it is technically demanding and labor intensive. However, immunohistochemistry on kidney biopsy specimens is feasible for nongenetic diagnosis of ADTKD- MUC1 and therefore, a valid method to select families for further diagnostics. Our data are compatible with the hypothesis that specific molecular effects of MUC1-fs underlie the pathogenesis of this disease.
The maize W22 genome provides a foundation for functional genomics and transposon biology
Authors: Nathan M. Springer, Sarah N. Anderson, Carson M. Andorf, Kevin R. Ahern, Fang Bai, Omer Barad, W. Brad Barbazuk, Hank W. Bass, Kobi Baruch, Gil Ben-Zvi, Edward S. Buckler, Robert Bukowski, Michael S. Campbell, Ethalinda K. S. Cannon, Paul Chomet, R. Kelly Dawe, Ruth Davenport, Hugo K. Dooner, Limei He Du, Chunguang Du, Katherine A. Easterling, Christine Gault, Jiahn-Chou Guan, Charles T. Hunter, Georg Jander, Yinping Jiao, Karen E. Koch, Guy Kol, Tobias G. Köllner, Toru Kudo, Qing Li, Fei Lu, Dustin Mayfield-Jones, Wenbin Mei, Donald R. McCarty, Jaclyn M. Noshay, John L. Portwood, Gil Ronen, A. Mark Settles, Doron Shem-Tov, Jinghua Shi, Ilya Soifer, Joshua C. Stein, Michelle C. Stitzer, Masaharu Suzuki, Daniel L. Vera, Erik Vollbrecht, Julia T. Vrebalov, Doreen Ware, Sharon Wei, Kokulapalan Wimalanathan, Margaret R. Woodhouse, Wenwei Xiong, Thomas P. Brutnell
Journal: Nature Genetics (2018)

The maize W22 inbred has served as a platform for maize genetics since the mid twentieth century. To streamline maize genome analyses, we have sequenced and de novo assembled a W22 reference genome using short-read sequencing technologies. We show that significant structural heterogeneity exists in comparison to the B73 reference genome at multiple scales, from transposon composition and copy number variation to single-nucleotide polymorphisms. The generation of this reference genome enables accurate placement of thousands of Mutator (Mu) and Dissociation (Ds) transposable element insertions for reverse and forward genetics studies. Annotation of the genome has been achieved using RNA-seq analysis, differential nuclease sensitivity profiling and bisulfite sequencing to map open reading frames, open chromatin sites and DNA methylation profiles, respectively. Collectively, the resources developed here integrate W22 as a community reference genome for functional genomics and provide a foundation for the maize pan-genome. Sequencing and de novo assembly of the maize W22 reference genome enable accurate placement of Mutator (Mu) and Dissociation (Ds) transposable element insertions, providing a foundation for maize functional genomics and transposon biology.
Medical Therapy for Heart Failure With Reduced Ejection Fraction
Authors: Stephen J. Greene, Javed Butler, Nancy M. Albert, Adam D. DeVore, Puza P. Sharma, Carol I. Duffy, C. Larry Hill, Kevin McCague, Xiaojuan Mi, J. Herbert Patterson, John A. Spertus, Laine Thomas, Fredonia B. Williams, Adrian F. Hernandez, Gregg C. Fonarow
Journal: Journal of the American College of Cardiology (2018)
Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding
Authors: Virginia Hernández‐Gea, Bogdan Procopet, Álvaro Giráldez, Lucio Amitrano, Candid Villanueva, Dominique Thabut, Luis Ibañez‐Samaniego, Gilberto Silva‐Junior, Javier Martinez, Joan Genescà, Christophe Bureau, Jonel Trebicka, Elba Llop, Wim Laleman, Jose Maria Palazon, Jose Castellote, Susana Rodrigues, Lise L. Gluud, Carlos Noronha Ferreira, Rafael Barcelo, Nuria Cañete, Manuel Rodríguez, Arnulf Ferlitsch, Jose Luis Mundi, Henning Gronbaek, Manuel Hernández‐Guerra, Romano Sassatelli, Alessandra Dell’Era, Marco Senzolo, Juan G. Abraldes, Manuel Romero‐Gómez, Alexander Zipprich, Meritxell Casas, Helena Masnou, Massimo Primignani, Aleksander Krag, Frederik Nevens, Jose Luis Calleja, Christian Jansen, Marie Angèle Robic, Irene Conejo, Maria‐Vega Catalina, Agustin Albillos, Marika Rudler, Edilmar Alvarado, Maria Anna Guardascione, Marcel Tantau, Jaime Bosch, Ferran Torres, Juan Carlos Garcia‐Pagán
Journal: Hepatology (2018)

Patients admitted with acute variceal bleeding (AVB) and Child-Pugh C score (CP-C) or Child-Pugh B plus active bleeding at endoscopy (CP-B+AB) are at high risk for treatment failure, rebleeding, and mortality. A preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) has been shown to improve survival in these patients, but its use in clinical practice has been challenged and not routinely incorporated. The present study aimed to further validate the role of preemptive TIPS in a large number of high-risk patients. This multicenter, international, observational study included 671 patients from 34 centers admitted for AVB and high risk of treatment failure. Patients were managed according to current guidelines, and use of drugs and endoscopic therapy (D+E) or p-TIPS was based on individual center policy. p-TIPS in the setting of AVB is associated with a lower mortality in CP-C patients compared with D+E (1 year mortality 22% vs. 47% in D+E group; P = 0.002). Mortality rate in CP-B+AB patients was low, and p-TIPS did not improve it. In CP-C and CP-B+AB patients, p-TIPS reduced treatment failure and rebleeding (1-year cumulative incidence function probability of remaining free of the composite endpoint: 92% vs. 74% in the D+E group; P = 0.017) and development of de novo or worsening of previous ascites without increasing rates of hepatic encephalopathy. Conclusion: p-TIPS must be the treatment of choice in CP-C patients with AVB. Because of the strong benefit in preventing further bleeding and ascites, p-TIPS could be a good treatment strategy for CP-B+AB patients.
FACE-Q Skin Cancer Module: appearance satisfaction and QoL
Authors: E.H. Lee, A.F. Klassen, S.J. Cano, K.S. Nehal, A.L. Pusic
Journal: British Journal of Dermatology (2018)

People who have surgery to remove skin cancer on the face are often left with a scar. After surgery, a patient's satisfaction with their appearance is an important but often overlooked treatment outcome (meaning goal), and a patient's opinion on the aesthetic outcome of their surgery (meaning how much it affects how they look) may differ from the surgeon's. Studies have shown that the patient's perspective of their facial scar after skin cancer surgery can influence their perception of the care they received, and their quality of life. This study tested the ‘Face‐Q Skin Cancer Module’, designed to measure facial and scar appearance, appearance‐related psychosocial distress (how much the scar impacts on the patient's emotional wellbeing), cancer worry and the patient experience. Each of these scales within the Face‐Q Skin Cancer Module was tested using responses from 209 patients undergoing facial skin cancer surgery, and the study found that the FACE‐Q Skin Cancer Module provides doctors with a comprehensive set of meaningful and scientifically sound set of scales for the facial skin cancer population. This Module will be useful in clinics with patients, but also in research.
Annals Story Slam - Who Knew?
Authors: Douglas M. DeLong
Journal: Annals of Internal Medicine (2018)

Web Exclusives17 July 2018Annals Story Slam - Who Knew?FREEDouglas M. DeLong, MDDouglas M. DeLong, MDBassett Healthcare, Cooperstown, New York (D.M.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0018 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Who Knew? "Who Knew?" by Douglas M. DeLong (Duration 4:30)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Bassett Healthcare, Cooperstown, New York (D.M.D.)Corresponding Author: Douglas M. DeLong, MD; e-mail, douglas.[email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 July 2018Volume 169, Issue 2Page: SS1 ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.Loading ...
Risk Score for Predicting Outcome in Patients With Asymptomatic Aortic Stenosis
Authors: Jean-LucMonin, PatrizioLancellotti, MehranMonchi, PascalLim, EmmanuelWeiss, LucPiérard, PascalGuéret
Journal: Circulation (2009)

Background— The management of patients with asymptomatic severe aortic stenosis remains controversial. We sought to develop a continuous risk score for predicting the midterm development of symptoms or adverse events in this setting. Methods and Results— We prospectively followed 107 patients with asymptomatic aortic stenosis (aged 72 years [63 to 77]; 35 women; aortic-jet velocity, 4.1 m/s [3.5 to 4.4]) at a single center in France. Predefined end points for assessing outcome were the occurrence within 24 months of death or aortic valve replacement necessitated by symptoms or by a positive exercise test. Variables independently associated with outcome were used to build a score that was validated in an independent cohort of 107 patients from Belgium. Independent predictors of outcome were female sex, peak aortic-jet velocity, and B-type natriuretic peptide at baseline. Accordingly, the score could be calculated as follows: Score=[peak velocity (m/s)×2]+(natural logarithm of B-type natriuretic peptide×1.5...
Liver‐Selective MMP‐9 Inhibition in the Rat Eliminates Ischemia‐Reperfusion Injury and Accelerates Liver Regeneration
Authors: Xiangdong Wang, Ana C. Maretti‐Mira, Lei Wang, Laurie D. DeLeve
Journal: Hepatology (2018)

Recruitment of liver sinusoidal endothelial cell progenitor cells (sprocs) from the bone marrow by vascular endothelial growth factor‐stromal cell‐derived factor‐1 (VEGF‐sdf‐1) signaling promotes recovery from injury and drives liver regeneration. Matrix metalloproteinases (MMPs) can proteolytically cleave VEGF, which might inhibit progenitor cell recruitment, but systemic matrix metalloproteinase inhibition might prevent efflux of progenitors from the bone marrow. The hypothesis for this study was that liver‐selective MMP‐9 inhibition would protect the hepatic VEGF‐sdf‐1 signaling pathway, enhance bone marrow sproc recruitment, and thereby ameliorate liver injury and accelerate liver regeneration, whereas systemic MMP inhibition would impair bone marrow sproc mobilization and therefore have less benefit or be detrimental. We found that liver‐selective MMP‐9 inhibition accelerated liver regeneration after partial hepatectomy by 40%, whereas systemic MMP inhibition impaired liver regeneration. Liver‐selective MMP‐9 inhibition largely abolished warm ischemia‐reperfusion injury. In the extended hepatectomy model, liver‐selective MMP‐9 inhibition restored liver sinusoidal endothelial cell integrity, enhanced liver regeneration, and reduced ascites. Liver‐selective MMP‐9 inhibition markedly increased recruitment and engraftment of bone marrow sprocs, whereas systemic MMP inhibition impaired mobilization of bone marrow sprocs and their hepatic engraftment. Hepatic MMP‐9 proteolytically cleaved VEGF after partial hepatectomy. Liver‐selective MMP‐9 inhibition prevented VEGF cleavage and doubled protein expression of VEGF and its downstream signaling partner sdf‐1. In contrast, systemic MMP inhibition enhanced recruitment and engraftment of infused allogeneic progenitors. Conclusion : Liver‐selective MMP inhibition prevents proteolytic cleavage of hepatic VEGF, which enhances recruitment and engraftment of bone marrow sprocs after liver injury. This ameliorates injury and accelerates liver regeneration. Liver‐selective MMP‐9 inhibition may be a therapeutic tool for liver injury that damages the vasculature, whereas systemic MMP inhibition can enhance the benefit of stem cell therapy with endothelial progenitor cells.
Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
Authors: Pavlo Gilchuk, Natalia Kuzmina, Philipp A. Ilinykh, Kai Huang, Bronwyn M. Gunn, Aubrey Bryan, Edgar Davidson, Benjamin J. Doranz, Hannah L. Turner, Marnie L. Fusco, Matthew S. Bramble, Nicole A. Hoff, Elad Binshtein, Nurgun Kose, Andrew I. Flyak, Robin Flinko, Chiara Orlandi, Robert Carnahan, Erica H. Parrish, Alexander M. Sevy, Robin G. Bombardi, Prashant K. Singh, Patrick Mukadi, Jean Jacques Muyembe-Tamfum, Melanie D. Ohi, Erica Ollmann Saphire, George K. Lewis, Galit Alter, Andrew B. Ward, Anne W. Rimoin, Alexander Bukreyev, James E. Crowe
Journal: Immunity (2018)

Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules.
Risk of Breast Implant–Associated Anaplastic Large Cell Lymphoma
Authors: Eric Swanson
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 17813: Magnetic Resonance T2 Mapping Enables Hemorrhage Isualization After Acute Myocardial Infarction in Swine
Authors: Haiyan Ding, M. Muz Zviman, Henry Halperin, Roy Beinart, Daniel A Herzka
Journal: Circulation (2012)

Introduction: Myocardial hemorrhage secondary to myocardial infarction (MI), as detected by MRI, is related to microvascular obstruction (MVO), which is associated with adverse prognosis. T2-based ...
Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett’s Esophagus to Esophageal Adenocarcinoma
Authors: Nour Hamade, Sreekar Vennelaganti, Sravanthi Parasa, Prashanth Vennalaganti, Srinivas Gaddam, Manon C.W. Spaander, Sophie H. van Olphen, Prashanthi N. Thota, Kevin F. Kennedy, Marco J. Bruno, John J. Vargo, Sharad Mathur, Brooks D. Cash, Richard Sampliner, Neil Gupta, Gary W. Falk, Ajay Bansal, Patrick E. Young, David A. Lieberman, Prateek Sharma
Journal: Clinical Gastroenterology and Hepatology (2018)
Response by Morello et al to Letters Regarding Article, “Diagnostic Accuracy of the Aortic Dissection Detection Risk Score Plus D–Dimer for Acute Aortic Syndromes: The ADvISED Prospective Multicenter Study”
Authors: Fulvio Morello, Christian Mueller, Alexandre de Matos Soeiro, Bernd A. Leidel, Sibilla Anna Teresa Salvadeo, Peiman Nazerian
Journal: Circulation (2018)
Assessment of Women Physicians Among Authors of Perspective-Type Articles Published in High-Impact Pediatric Journals
Authors: Julie K. Silver, Julie A. Poorman, Julia M. Reilly, Nancy D. Spector, Richard Goldstein, Ross D. Zafonte
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Most pediatricians are women; however, women pediatricians are underrepresented in academic leadership positions such as department chairs and journal editors and among first authors of original research articles published in pediatric journals. Publication of all types of articles, particularly in high-impact specialty journals, is crucial to career building and academic success. <h3>Objective</h3> To examine the gender-related profile associated with authors of perspective-type articles in the 4 highest-impact general pediatric journals to determine whether women physicians were similarly underrepresented. <h3>Design and Setting</h3> Cross-sectional study of perspective-type articles published between 2013 and 2017 in the 4 highest-impact general pediatric journals:<i>Academic Pediatrics</i>,<i>JAMA Pediatrics</i>,<i>The Journal of Pediatrics</i>, and<i>Pediatrics</i>. <h3>Main Outcomes and Measures</h3> The primary outcome measure was the number and percentage of first-author women physicians as compared with men physicians. Secondary outcome measures included number and percentage of all men and all women among last authors and coauthors associated with physician first authors. <h3>Results</h3> A total of 425 perspective-type articles were identified, with physicians listed as the first author on 338 (79.5%). Women were underrepresented among physician first authors of known gender (140 of 336 [41.7%]), particularly among physician first authors of article categories described as scholarly (range, 15.4%-44.1%) vs categories described as narrative (range, 52.9%-65.6%) in nature. Women were also underrepresented among last authors and coauthors of articles attributed to both men and women physician first authors, although the underrepresentation of women among last authors and coauthors was more pronounced if a man physician was the first author. <h3>Conclusions and Relevance</h3> Because perspective-type articles provide an opportunity for authors to express their opinions, provide insights that may influence their field, and enhance their academic resumes, there is a need for pediatric journal editors and leaders of medical societies who are associated with these journals to ensure the equitable inclusion of women in medicine. A hallmark of best practices for diversity and inclusion in academic medicine is transparency with regard to reporting of gender disparities in all areas of scholarship attribution and credit.
Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure
Authors: Raza M. Alvi, Anne M. Neilan, Noor Tariq, Magid Awadalla, Maryam Afshar, Dahlia Banerji, Adam Rokicki, Connor Mulligan, Virginia A. Triant, Markella V. Zanni, Tomas G. Neilan
Journal: Journal of the American College of Cardiology (2018)